“…Previous studies have shown that ARBs perform better than ACEi in respiratory disorders such as ARDS induced by bacterial infection, as angiotensin II can be synthesized by some alternative enzymes such as chymase, cathepsin and trypsin [9,10]. Thus in our study, we focused on losartan, the first orally active non-peptide selective ARB, to further investigate its therapeutic role in ALI induced by H5N1 virus.…”